Compare FedEx Corporation (FDX) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Mesoblast Limited — how do they compare? FedEx Corporation trades at $292.44 (market cap $69.04B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: FedEx Corporation is far larger — about 39.5× Mesoblast Limited's market cap, and FedEx Corporation pays a 1.67% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Mesoblast Limited for 14 Days on average.
| FDX | MESO | |
|---|---|---|
Market Cap | $69.04B | $1.75B |
Volume | 1,287,367 | 239,027 |
Sector | Industrials | Health |
52-Week High | $339.35 | $20.96 |
52-Week Low | $180.87 | $13.19 |
Typical Hold Time | 87 Days | 14 Days |
Enterprise Value | $98.68B | $1.83B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FDX trades at $289.04, flat on the day, with a bearish technical signal from moving averages and ADX indicators. The company reported revenue of $87.93B for 2025, with a net income margin of 4.68% and a P/E ratio of 15.58. Recent news includes a $300 million order for electric trucks from Harbinger and shareholder approval of executive compensation at the annual meeting.
The outlook is mixed, with strong analyst buy consensus (57%) and a price target of $307.55 offering upside potential, but risks from rising fuel costs and a bearish technical trend suggest near-term volatility. Earnings beats in recent quarters support fundamental strength, yet macroeconomic pressures on logistics margins warrant caution.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
